Zota Health CareNSE:ZOTA +0.35%77 EBITDA Margin % is 3.62% as of Mar. 2026, which is 45% below its 10-year median of 6.63. GuruFocus rates NSE:ZOTA with a GF Score™ of 77/100 and a GF Value™ of ₹1,568.77 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Zota Health Care ranks better than 69.6% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zota Health Care's EBITDA for the
three
months ended in Mar. 2026 was ₹59 Mil. Zota Health Care's Revenue for the
three
months ended in Mar. 2026 was ₹1,632 Mil. Therefore, Zota Health Care's EBITDA margin for the quarter that ended in Mar. 2026 was 3.62%.
Zota Health Care (NSE:ZOTA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zota Health Care EBITDA Margin % Related Terms
Zota Health Care EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zota Health Care's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ZOTA vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Zota Health Care's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zota Health Care EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zota Health Care's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zota Health Care's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zota Health Care (NSE:ZOTA) has a EBITDA Margin % of 3.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zota Health Care and its competitors. This is 45% below median its historical median of 6.63. According to the industry distribution chart, Zota Health Care ranks #287 out of 944 companies in the Biotechnology industry, placing it in the top 30.4%.
Is Zota Health Care's EBITDA Margin % too high?
Zota Health Care's current EBITDA Margin % of 3.62% is 45% below median its 10-year median of 6.63. Based on the distribution chart, Zota Health Care ranks #287 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zota Health Care has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zota Health Care's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zota Health Care ranks #287 out of 944 companies for EBITDA Margin %. This puts Zota Health Care in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zota Health Care and its competitors. Zota Health Care's current EBITDA Margin % is 3.62%, which is 45% below median its own 10-year median of 6.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zota Health Care stock overvalued right now?
Based on GuruFocus' analysis, Zota Health Care (NSE:ZOTA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,568.77, compared to a current price of ₹1,389.50 — trading 11.4% below its estimated fair value. The current EBITDA Margin % is 3.62%, which is 45% below median its 10-year median of 6.63. Zota Health Care's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zota Health Care (NSE:ZOTA), the current EBITDA Margin % is 3.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zota Health Care (NSE:ZOTA) Overvalued in 2026?
Based on GuruFocus' analysis, Zota Health Care stock appears to be undervalued.
The current stock price of ₹1,389.50 is trading 11.4% below its estimated GF Value™ of ₹1,568.77.
GuruFocus considers Zota Health Care to be Modestly Undervalued.
Key valuation signals for NSE:ZOTA:
EBITDA Margin %: 3.62% (45% below median its 10-year median of 6.63)
GF Value™: ₹1,568.77 vs. price of ₹1,389.50 (11.4% below fair value)
No single metric tells the full story. See the NSE:ZOTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zota Health Care Ltd is engaged in the manufacturing, trading, and export of pharmaceutical products. The company caters to both domestic and international markets. It offers a vast range of pharmaceutical, nutraceutical, ayurvedic, and OTC products in India and overseas as well.
77GF Score
Get the complete analysis for NSE:ZOTA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZOTA has been successfully added to your 
